General Hospital Arcispedale Santa Maria Nuova (ASMN) – Reggio Emilia
The Research Institute for Advanced Technologies and Healthcare Models in Oncology is a 193-bed Research Cancer Center embedded in the context of the Local Health Authority of Reggio Emilia. It was acknowledged as oncological Research Hospital (IRCCS) in 2011 by the Italian Ministry of Health as part of the General Hospital Arcispedale Santa Maria Nuova (ASMN) located in Reggio Emilia. The clinical activities are coupled with the Translational Research Laboratories and the Research and Statistics Infrastructure to guarantee methodological and statistical competences and provide qualified support to research activities including the data management and the grant office. In the last years, the Hospital has been re-organized under the principles of Intensity of Care and by the integrated-care approach, thanks to the development of Care Pathways (CP) and to the multi-professional team working.
To date the following CP have been implemented and consolidated: Thyroid, Breast, Skin, Lung, Ovary, Colorectal, Prostate, HCC, Pancreatic, Lymphoma and glioma. In addition to the multidisciplinary teams of CP, other clinical cases related to oncological diseases are discussed by multidisciplinary groups that guarantee the patient a comprehensive approach to disease (gynaecological, gastrointestinal, head-neck cancers, mesothelioma and myeloma).
ASMN research activities, both oncological and non-oncological, have sharply improved in the last years, with a substantial increase of dedicated staff, facilities, projects and outputs. In 2016 the IRCCS counted 179 ongoing oncological clinical trials out of a total of 329 oncological studies. 39 pharmacological CT were started in 2016. More than 400 scientific papers authored by the IRCCS researchers were published in international journals in 2016, 200 of which were oncological.
In accordance to the Italian National Plan of Healthcare Research, the IRCCS oncological research is organised in four Research Lines as follows:
- Complex Oncological Pathology, facing the complexity of the cancer patient by developing pathways which are modelled to suit the clinical needs and, the biological, genetic and individual patient’s characteristics.
- Advanced Diagnostic and Therapeutic Technologies, studying and evaluating new health technologies (e.g., drugs, diagnostics, devices, algorithms, classification systems) characterised by innovativeness.
- Healthcare Protocols and Oncological Pathways, developing, evaluating and validating complex clinical and/or organisational healthcare interventions.
- Targets and innovative therapeutic strategies in Oncology and Onco-hematology, studying tumour microenvironment, inflammation, angiogenesis, and immunity.
In 2016 the new 15 thousands square meters Onco-Haematological Centre (CORE) was opened, which houses the cancer wards and services (Haematology, Oncology, Cancer Surgeries, Digestive Endoscopy, Palliative Care, Psycho-oncology and Pharmacy) for a total of more than 88 inpatient-beds, 36 outpatient-beds, 5 endoscopy rooms, of which 1 operating room, and an Anticancer Drug Centralized Unit, and with more than 200 employees.
The IRCCS also recently set up new translational laboratories and acquired a innovating linear accelerator Varian True Beam for radiotherapy.
Consulta le singole schede dei nostri Soci